← All trials
NCT03312777
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2017
- Primary completion
- Dec 15, 2017
- Completion date
- Dec 22, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syntrix Biosystems, Inc.Lead sponsor
- Syntrix Biosystems, Inc.Study director
- Pharmaceutical Research Associates, Inc. (PRA)Overall official - principal investigator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- DF/Net ResearchCollaborator
- ITT Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.